Hospira

A Look At All Of Pfizer's Acquisitions Over The Past 2 Years

Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade

Pfizer Reports Better-Than-Expected Q4, Shares Dip Lower

Pfizer Receives FDA Approval For Cheaper Version Of Johnson & Johnson's Top Drug Remicade

Pfizer Reports Better-Than-Expected Q4, Shares Dip Lower

Why M&A Doesn't Make Sense For Pfizer Anytime Soon

Mizuho Analyst On The Fence At Medicines Co. Pending Patent Appeal

Why M&A Doesn't Make Sense For Pfizer Anytime Soon

Mizuho Analyst On The Fence At Medicines Co. Pending Patent Appeal

Fresenius SE, Permira Interested In Acquiring Danone's Medical Unit

Wedbush Initiates Coverage On Cubist Pharmaceuticals

Hospira Recent News

#PreMarket Primer: Monday, July 28: Tension Between U.S. And Israel On The Rise

Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke

Top Trending Tickers On StockTwits For February 12

Barron's Recap (2/9/12): Best Fund Families

Caterpillar, Discover Financial and Other Illinois Primary Stock Picks

Goldman Sachs Maintains Neutral on Hospira

Citi Maintains Sell Rating on Hospira

Morgan Stanley Reiterates Equal-Weight on Hospira

J.P. Morgan Maintains OW Rating on Hospira Following Management Meeting

Goldman Sachs Downgrades HSP To Neutral

UPDATE: J.P. Morgan Color On HSP Target Increase

JP Morgan Raises PT On Hospira To $66

Citigroup Downgrades Hospira To Sell, PT to $54

HSP's 1Q11 IMS Sales Are Improving, Morgan Stanley Reports

Morgan Stanley Increases HSP 1Q11 Estimates

Goldman Sachs Maintains Buy Rating On Hospira

Citigroup Upgrades Hospira To Hold, PT To $52

Goldman Sachs Lowers PT on Hospira to $59 (HSP)